Physician profile
Andrew House
NPI 1528521697
$1,802.21
in general payments reported to CMS, 2019-2025
21 companies · $938 in 2025
The $938 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $19.71 · 2021: $122 · 2022: $76.47 · 2023: $83.73 · 2024: $562 · 2025: $938.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,584.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,584.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $265.09 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Boston Scientific Corporation | $187.54 | 2024-2025 | Watchman Flx |
| Amgen INC. | $181.07 | 2021-2025 | Repatha, Otezla, Otezla |
| Astrazeneca Pharmaceuticals LP | $166.09 | 2024-2025 | Breztri, Airsupra |
| Abbvie INC. | $165.50 | 2022-2025 | |
| Pfizer INC. | $128.05 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $109.14 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $73.39 | 2024-2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $66.34 | 2025 | Auvelity |
| Abbott Laboratories | $61.11 | 2025 | Freestyle Libre 3 |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $53.26 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $48.60 | 2025 | Trintellix |
| Edwards Lifesciences Corporation | $44.30 | 2022-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Otsuka America Pharmaceutical, INC. | $39.95 | 2025 | Rexulti |
| Dexcom, INC. | $37.25 | 2025 | Dexcom G6 Transmitter |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $36.09 | 2023 | Mounjaro |
| Idorsia Pharmaceuticals US INC | $34.84 | 2023-2024 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.39 | 2024-2025 | Jardiance, Synjardy |
| Organon LLC | $29.02 | 2025 | Nexplanon |
| Lucid Diagnostics INC. | $28.56 | 2023 | |
| Sanofi Pasteur INC. | $13.63 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew House listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.